e16545 Background: The standard of care in locally advanced carcinoma cervix is concurrent chemoradiotherapy. The aim of the study is to prospectively assess quality of life (QoL) in patients of carcinoma cervix treated with chemoradiotherapy. Methods: Between June 2011 and June 2012, 20 patients of carcinoma cervix were included in the study. All patients received conformal external beam radiotherapy (EBRT) on Linear accelerator to a total dose of 50Gy, 2 Gy per fraction, 25 fractions to the pelvis and intracavitary brachytherapy by High dose rate brachytherapy, 7 Gy per fraction, 3 fractions to a total dose of 21 Gy. Patients received concurrent chemotherapy with Cisplatin 40 mg/m2 weekly for five weeks. QoL was assessed using EORTC QLQ-C30 and QLQ-C24 questionnaires at baseline and at six months following completion of treatment. The collected data was analyzed using standard statistical software package (SPSS version 20.0). Results: Median age of the patients in the study was 52years ( range 34 – 69 years), 13 (65%) patients were stage II and seven (35%) were stage III. Mean duration of treatment is 37 days (range 34- 70 days). Local control rate at six months was 95%. Compliance with completion of QoL scores was high. A statistically significant improvement (p = 0.001) was seen at six months post treatment in Global health score and in function scales like physical function, role function, emotional function, social function and cognitive function. There was a significant improvement in symptom scales of urologic and vaginal symptoms. The difference in sexual function at six months showed a trend towards significance (p = 0.052). Conclusions: Patients of carcinoma cervix have a significant improvement in quality of life following treatment with radiotherapy and chemotherapy.

e17028 Background: Concurrent chemoradiotherapy with three weekly cisplatin is the standard of care for organ preservation in locally advanced head and neck cancers. Quality of life (QoL) is vital in this strategy and this study aims to compare QoL in patients of locally advanced head and neck cancers treated with concurrent chemoradiation with either three weekly or weekly cisplatin regimen. Methods: Between January 2011 and May 2012, 30 patients of locally advanced head and neck cancer were divided into two arms each consisting of 15 patients. All patients received conformal radiotherapy (RT) on linear accelerator to a total dose of 70 Gy, 2 Gy per fraction over 35 fractions. Patients in Arm A received concurrent chemotherapy with Cisplatin 100mg/m2 given on day1,22,43. Patients in Arm B received concurrent chemotherapy with Cisplatin 40 mg/m2given weekly for seven weeks. QoL was assessed using EORTC QLQ-C30 and QLQ-H&N35 questionnaires at baseline, completion of RT and at one and two months following completion of treatment. The collected data was analyzed using standard statistical software package (SPSS version 20.0). Results: Median age in Arm A and Arm B were 45 years (range 23-67years) and 48 years (range 36-71) respectively. All patients completed the planned RT, 73% of patients in Arm A and 93% of patients in Arm B received the planned dose of chemotherapy. Compliance with completion of QoL questionnaires was high in both arms. QoL scores decreased during chemoradiotherapy in both arms, and the scores were better in Arm B without statistical significance. The QoL scores reached baseline earlier in the Arm B compared to Arm A for most of the function scales and symptom scales at second month follow up. There was no statistical difference between the two arms for most of the parameters, except for symptom scales of pain (p=0.029) at 1st month follow-up and swallowing (p=0.023) at 2ndmonth follow-up favouring Arm B. Conclusions: Chemoradiotherapy with weekly cisplatin 40mg/m2 with its better compliance and favourable quality of life can serve as an alternative for the conventional three weekly cisplatin regimen.